Organic compounds -- part of the class 532-570 series – Organic compounds – Four or more ring nitrogens in the bicyclo ring system
Reexamination Certificate
2006-06-20
2006-06-20
McKenzie, Thomas C. (Department: 1624)
Organic compounds -- part of the class 532-570 series
Organic compounds
Four or more ring nitrogens in the bicyclo ring system
C544S115000, C514S233200, C514S252160, C514S267000
Reexamination Certificate
active
07064204
ABSTRACT:
New compounds having a tricyclic pyrazolotriazolopyrimidine ring structure are provided and methods of using those compounds for a variety of therapeutic indications.
REFERENCES:
patent: 6407236 (2002-06-01), Baraldi et al.
patent: 6448253 (2002-09-01), Baraldi
patent: 6630475 (2003-10-01), Neustadt et al.
patent: 2003/0212059 (2003-11-01), Boyle et al.
patent: WO 95/01356 (1995-01-01), None
patent: WO 97/05138 (1997-02-01), None
patent: WO 00/15231 (2000-03-01), None
patent: WO 01/92264 (2001-06-01), None
Luo Yan; Joachim C. Burbiel; Astrid Maaβ; Christa E. Müller, Expert Opinion on Emerging Drugs 2003, vol. 8, No. 2, pp. 537 - 576.
Pier Giovanni Baraldi; Allan R Moorman; Mojgan Aghazadeh Tabrizi; MariaGiovanna Pavani; Romeo Romagnoli, Expert Opinion on Therapeutic Patents, 2004, vol. 14, No. 1, pp. 71-79.
P.G. Baraldi; B. Cacciari; R. Romagnoli; G. Spalluto, Expert Opinion on Therapeutic Patents, 1999, vol. 9, No. 5, pp. 515-527.
Popoli, P. et al, Curr. Med. Chem., 2004, 4, pp. 1-11.
Kiec-Kononowicz, K. et al, Pure Appl. Chem., 73, 2001, pp. 1411-1420.
Hess, Sonja, Expert Opinion Ther. Patents, 2001, 11, pp. 1533-1561.
F. Gatta, et al., “Synthesis of imidazo[1,2-c]pyrazolo[4,3-e]pyrimidines, pyrazolo [4,3-e]1,2,4-triazolo[1,5-c]pyrimidines and 1,2,4-triazolo[5,1-i]purines: new potent adenosine A2receptor antagonists,” European Journal of Medicinal Chemistry (1993), vol. 28, Nos. 7/8, pp. 569-576, XP009002008.
P. Baraldi, et al., “Pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine Derivatives as Highly Potent and Selective Human A3Adenosine Receptors Antagonists: Influence of the Chain at the N8Pyrazole Nitrogen,” Journal of Medicinal Chemistry (2000), vol. 43, No. 25, pp. 4768-4780, XP-002256635.
P. Baraldi, et al., Design, Synthesis, and Biological Evaluation of C9—and C2Substituted Pyrazolo [4,3-e]-1,2,4-trizolo [1,5-c]pyrimidines as new A2Aand A3Adenosine Receptor Antagonists, Journal of Medicinal Chemistry (2003), vol. 46, No. 7, pp. 1229-1241, XP-002256636.
A copy of the Annex to Form PCT/ISA/206 (Communication Relating to the Results of the Partial International Search), dated Oct. 28, 2003.
P. Baraldi, et al., “Synthesis Biological Activity, and Molecular Modeling Investigation of New Pyrazolo [4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine Derivatives as Human A3Adenosine Receptor Agonists”, Journal of Medicinal Chemistry, vol. 45, No. 4, Feb. 14, 2002, pp. 770-780, XP002271430.
A copy of the International Search Report dated Mar. 29, 2004, issued in corresponding application No. PCT/US03/17313.
Baraldi Pier Giovanni
Borea Pier Andrea
Jones Day
King Pharmacueticals Reserch and Development, Inc.
McKenzie Thomas C.
LandOfFree
Pharmaceutically active compounds having a tricyclic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutically active compounds having a tricyclic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutically active compounds having a tricyclic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3705041